Cocaine peptide interactions
BPC-157 {#bpc-157}
Most relevant peptide for cocaine — indirect evidence from amphetamine/methamphetamine literature.
- Blocks amphetamine-induced stereotypy and haloperidol-induced supersensitivity
- Counteracts DA, 5-HT, glutamate, GABA, NE, ACh, and NO system disturbances
- Acts as a dopamine system stabiliser — not just a blocker or agonist, but a system normaliser
- Limits efficacy of dopamine agonists (could theoretically blunt cocaine’s euphoric effect)
- Counteracts sensitisation from chronic methamphetamine — directly applicable to cocaine (same DAT mechanism)
- No direct cocaine studies — only amphetamine/methamphetamine data; mechanism directly extrapolatable
- Unclear if this helps or hurts cocaine crash recovery — BPC-157’s stabilising action could theoretically help restore dopaminergic function, but this is untested
Clinical relevance: Most evidence-based peptide interaction in the stack for cocaine. Dopamine stabiliser profile makes it theoretically interesting for crash mitigation, but no human cocaine data.
Retatrutide {#retatrutide}
Appetite suppression compounding — goal conflict, not toxicity. BMJ 2026 data suggests potential benefit.
- Cocaine is a potent appetite suppressant (DAT/NET-mediated anorexigenic effect)
- Retatrutide (GLP-1/GIP/glucagon agonist) is an appetite suppressant
- Additive anorexia risk — theoretically significant but not documented
- BMJ 2026 (n=524,817 veterans): GLP-1 RAs associated with reduced risk of incident cocaine use disorder — first large-scale epidemiological signal suggesting protective effect
- Preclinical: GLP-1 agonism attenuates cocaine reward via DA/GABA/glutamate modulation and reduced neuroinflammation
- Semaglutide reduced opioid overdose risk 42–68% vs other glucose-lowering meds — class effect plausible
- No direct cardiotoxic interaction between GLP-1 agonists and cocaine identified; GLP-1 RAs associated with reduced cardiovascular risk overall
Clinical relevance: Appetite suppression compounding is a monitoring flag. No acute cardiotoxicity concern. The Retatrutide–CUD risk reduction signal is promising but not yet actionable for harm reduction.
TB-500 (Thymosin β4) {#tb-500}
Likely not relevant — wrong cardiomyopathy mechanism.
- Tβ4 initiates simultaneous myocardial and vascular regeneration in ischemic MI models
- Cocaine cardiomyopathy is NOT ischemic MI — it’s microvascular spasm + direct myocardial toxicity + oxidative stress
- Repair pathways may not overlap
- No TB-500 + cocaine cardiomyopathy literature exists
Clinical relevance: Not practically relevant. TB-500’s repair mechanism is for ischemic damage.
GHK-Cu {#ghk-cu}
Likely safe — no concern documented.
- Documented anti-inflammatory and antioxidant properties
- No literature on GHK-Cu + cocaine-induced oxidative stress specifically
- Naturally occurring peptide, well-tolerated
- No serious adverse effects documented
- Same theoretical Fenton/copper question as alcohol — likely debunked for same reasons
Clinical relevance: No documented concern. Likely safe in this context.
Cocaethylene interaction note
Cocaethylene is formed via CES1-mediated transesterification when ethanol is present. No peptide is known to affect this pathway. Retatrutide’s GLP-1 effects do not meaningfully interact with cocaethylene formation.
Summary table
| Peptide | Cocaine relevance | Evidence quality | Concern |
|---|---|---|---|
| BPC-157 | Dopamine stabiliser; sensitisation counteraction | Amphetamine literature (direct); cocaine extrapolation | Theoretical — may help crash, may blunt high |
| Retatrutide | Additive appetite suppression | Observational + preclinical | Monitor; no acute toxicity |
| TB-500 | Cardiac repair | Wrong mechanism (ischemic vs cocaine cardiomyopathy) | Not relevant |
| GHK-Cu | Antioxidant | No cocaine data; GHK-Cu safety well-established | Likely safe |